PDGFRB and idiopathic pulmonary fibrosis: Nintedanib, a triple RTK inhibitor that blocks PDGFR, VEGFR, and FGFR, exhibits a powerful anti-fibrotic effect, and has been approved by the FDA for treatment of idiopathic pulmonary fibrosis (IPF) [18].